These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27649305)

  • 1. In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013.
    Maroun R; Maunoury F; Benjamin L; Nachbaur G; Durand-Zaleski I
    PLoS One; 2016; 11(9):e0162864. PubMed ID: 27649305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
    Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
    Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
    BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of Clostridium difficile Infections in French Hospitals in 2014 From the National Health Insurance Perspective.
    Leblanc S; Blein C; Andremont A; Bandinelli PA; Galvain T
    Infect Control Hosp Epidemiol; 2017 Aug; 38(8):906-911. PubMed ID: 28756805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study.
    Touat M; Opatowski M; Brun-Buisson C; Cosker K; Guillemot D; Salomon J; Tuppin P; de Lagasnerie G; Watier L
    Appl Health Econ Health Policy; 2019 Jun; 17(3):381-389. PubMed ID: 30506456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of dengue in three French territories of the Americas: an analysis of the hospital medical information system (PMSI) database.
    Uhart M; Blein C; L'Azou M; Thomas L; Durand L
    Eur J Health Econ; 2016 May; 17(4):497-503. PubMed ID: 25962729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of osteoporosis in women: data from the 2008 French hospital database (PMSI).
    Maravic M; Jouaneton B; Vainchtock A; Tochon V
    Clin Exp Rheumatol; 2012; 30(2):222-7. PubMed ID: 22546070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital burden of pulmonary arterial hypertension in France.
    Bergot E; De Leotoing L; Bendjenana H; Tournier C; Vainchtock A; Nachbaur G; Humbert M
    PLoS One; 2019; 14(9):e0221211. PubMed ID: 31536491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.
    Blein C; Gavazzi G; Paccalin M; Baptiste C; Berrut G; Vainchtock A
    BMC Infect Dis; 2015 Aug; 15():350. PubMed ID: 26286598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs associated with hospitalization in HIV-positive patients in France.
    de Léotoing L; Yazdanpanah Y; Finkielsztejn L; Chaize G; Vainchtock A; Nachbaur G; Aubin C; Bonnet F
    AIDS; 2018 Sep; 32(14):2059-2066. PubMed ID: 29894390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.
    Cholley T; Thiery-Vuillemin A; Limat S; Hugues M; Calcagno F; Mouillet G; Anota A; Nerich V
    Clin Genitourin Cancer; 2019 Feb; 17(1):e227-e234. PubMed ID: 30502046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database.
    St Guily JL; Borget I; Vainchtock A; Rémy V; Takizawa C
    Head Neck Oncol; 2010 Sep; 2():22. PubMed ID: 20809978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
    Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
    JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
    Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National trends and determinants of hospitalization costs and lengths-of-stay for uterine fibroids procedures.
    Becker ER
    J Health Care Finance; 2007; 33(3):1-16. PubMed ID: 19175228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant-related hospital admissions: serious adverse reactions identified through hospital databases.
    Heng C; Rybarczyk-Vigouret MC; Michel B
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):144-51. PubMed ID: 25079654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
    Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
    Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries.
    Lafuma A; Cotté FE; Le Tourneau C; Emery C; Gaudin AF; Torreton E; Gourmelen J; Bonastre J
    J Med Econ; 2019 Jul; 22(7):698-705. PubMed ID: 30895832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.